DTwP-HepB-Hib-IPV Hexavalent vaccine

LG Chem is developing a hexavalent combination vaccine (DTwP-HepB-Hib-IPV) to improve vaccine accessibility and affordability in low- and middle-income countries. The market is transitioning from pentavalent vaccines plus separate IPV to hexavalent formulations, thereby reducing the number of
immunization visits. While WHO has prioritized the prequalification of hexavalent vaccine, limited supply remains a challenge. With previous support from the RIGHT Foundation support, LG Chem scaled production from pilot to commercial scale and completed aseptic process validation. This grant supports
a Phase 2 clinical trial in the Philippines to evaluate improved immunogenicity of a reformulated pertussis component.